|
Mental Depression
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
During the 3-month follow-up, 76 patients were defined as depression (24.5%; 95% confidence interval [CI]: 17.9%-29.3%), and GDF-15 levels in those patients were nearly more than 1 time greater as compared with patients who were free of depression (P < 0.001).
|
31561112 |
2020 |
|
Depressive disorder
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
During the 3-month follow-up, 76 patients were defined as depression (24.5%; 95% confidence interval [CI]: 17.9%-29.3%), and GDF-15 levels in those patients were nearly more than 1 time greater as compared with patients who were free of depression (P < 0.001).
|
31561112 |
2020 |
|
Hepatitis B
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Together, these results suggest that upregulation of GDF15, downregulation of FT and FT/E2 ratio may be involved in the outcome of HBV infection and the severity of HCC.
|
31766097 |
2020 |
|
Aortic Aneurysm, Abdominal
|
0.010 |
Biomarker
|
disease |
BEFREE |
Combination of growth/differentiation factor 15 and cystatin B had the best ability to discriminate abdominal aortic aneurysm from non-abdominal aortic aneurysm (area under the curve, 0.76; sensitivity, 80% and specificity, 52%).
|
31466471 |
2020 |
|
Metabolic myopathy
|
0.010 |
Biomarker
|
group |
BEFREE |
Our findings indicate that elevated GDF-15 can distinguish patients with mitochondrial myopathy from other myopathies, including metabolic myopathies.
|
31669236 |
2020 |
|
Depressed mood
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
During the 3-month follow-up, 76 patients were defined as depression (24.5%; 95% confidence interval [CI]: 17.9%-29.3%), and GDF-15 levels in those patients were nearly more than 1 time greater as compared with patients who were free of depression (P < 0.001).
|
31561112 |
2020 |
|
Sinistrocardia
|
0.010 |
Biomarker
|
disease |
BEFREE |
In fact, we found that H-FABP levels were primarily elevated in group 2 and 3 PH, whereas the concentrations of GDF-15 and suPAR were primarily associated with pulmonary hypertension due to left sided heart disease (group 2).
|
31327702 |
2020 |
|
Macrovascular disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
In patients with DKD, GDF-15 was significantly associated with increased risk of MACE after adjustments for baseline age, sex, microalbuminuria, and kidney function and (59 MACE events during 7 years follow-up, hazard ratio per standard deviation increase 1.43 [95% CI 1.03-1.98]) but not after further adjustments for cardiovascular risk factors.<b>Conclusion:</b> Our proteomics approach confirms and extends previous associations of higher circulating levels of GDF-15 with both micro- and macrovascular disease in patients with type 2 diabetes.
|
31805809 |
2020 |
|
Post stroke depression
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Using the ROC curves, GDF-15 serum level at 1660 ng/l predicted the PSD with the highest sensitivity and specificity [67.1% and 77.4%, respectively; AUC=0.78, 95%CI: 0.72-0.84; P < 0.001].
|
31561112 |
2020 |
|
Heart failure with preserved ejection fraction [HFpEF]
|
0.010 |
Biomarker
|
disease |
BEFREE |
In HFpEF, a decrease in peak VO<sub>2</sub> was associated with an increase in NT-proBNP (-0.726 mL/min/kg per doubling, 95% CI -1.100 to -0.353, P < .001), and a decrease in 6MWD was associated with an increase in growth differentiation factor-15 (-31.606 m per doubling, 95% CI -61.404 to -1.809, P = .038).
|
31805424 |
2020 |
|
Amyotrophic Lateral Sclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, the results revealed that GDF-15 may be influenced by EDSS in MS/NMOPSD and by age in LE, MS/NMOSD, and ALS but not in MD.
|
31476622 |
2019 |
|
Anemia of chronic disease
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The concomitant presence of kidney failure, especially chronic kidney disease (CKD) and MM per se, leading to anaemia of chronic disease (ACD) in combination, provoked us to pose the question about their reciprocal dependence and relationship with specific biomarkers; namely, soluble transferrin receptor (sTfR), growth differentiation factor 15 (GDF15), hepcidin 25 and zonulin.
|
31683939 |
2019 |
|
Malignant neoplasm of endometrium
|
0.010 |
Biomarker
|
disease |
BEFREE |
Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer.
|
30645608 |
2019 |
|
Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, the potential of serum hepcidin and serum GDF-15 as biomarkers that correlate with patient's survival in the two entities upper urinary tract urothelial carcinomas (UUTUC) and renal cell carcinoma (RCC) were analyzed.
|
30646851 |
2019 |
|
Carcinoma, Transitional Cell
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Serum Hepcidin and GDF-15 levels as prognostic markers in urothelial carcinoma of the upper urinary tract and renal cell carcinoma.
|
30646851 |
2019 |
|
Cerebrovascular Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Elevated GDF-15 concentrations are associated with increased risks of cardiovascular diseases, diabetes mellitus and cerebrovascular disease.
|
31446824 |
2019 |
|
Down Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Finally, persons with Down Syndrome (characterized by accelerated aging) have higher levels of GDF15 and HN with respect to their siblings, suggesting that these molecules, especially GDF15, could be considered markers of biological age.
|
29955888 |
2019 |
|
Fatigue
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Among the conditions in which circulating GDF15 levels are highly elevated are mitochondrial disorders, where early skeletal muscle fatigue is a key symptom.
|
31801546 |
2019 |
|
Chronic Fatigue Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
GDF15 levels were 491 pg/ml in controls (95% CI 429-553), 546 pg/ml (95% CI 478-614) in MS patients, 560 pg/ml (95% CI 502-617) in mild/moderate ME/CFS patients and 602 pg/ml (95% CI 531-674) in severely affected ME/CFS patients.
|
31801546 |
2019 |
|
Gaucher Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Although GDF-15 showed better analytical characteristics (sensitivity = 0.66, specificity = 0.64, area under the curve [AUC] = 0.88) compared to FGF-21 (sensitivity = 0.51, specificity = 0.76, AUC = 0.78) in the pediatric group of mitochondrial diseases, both markers were also elevated in a variety of non-mitochondrial diseases, especially those with liver involvement (Gaucher disease, galactosemia, glycogenosis types 1a, 1b, 9), organic acidurias and some leukodystrophies.
|
31260105 |
2019 |
|
Gigantism
|
0.010 |
Biomarker
|
disease |
BEFREE |
We obtained SNPs strongly (p value <5 × 10<sup>-8</sup>) predicting GDF-15 from a genome-wide association study (GWAS) (n = 5440) and applied them to genetic studies of CAD (CARDIoGRAMplusC4D 1000 Genomes-based GWAS [n = 184,305]), type 2 diabetes (DIAGRAM [DIAbetes Genetics Replication And Meta-analysis; n = 898,130]), glycaemic traits (MAGIC [the Meta-Analyses of Glucose and Insulin-related traits Consortium; HbA<sub>1c</sub>: n = 123,665; fasting glucose: n = 46,186]), BP, breast cancer and colorectal cancer (UK Biobank [n ≤ 401,447]), lipids (GLGC [Global Lipids Genetic Consortium; n ≤ 92,820]) and adiposity (GIANT [Genetic Investigation of ANthropometric Traits Consortium; n = 681,275]).
|
31161347 |
2019 |
|
Focal glomerulosclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Importantly, GDF15 was found to be involved in podocyte pathogenesis, where GDF15 was upregulated in glomeruli of patients with focal segmental glomerulosclerosis.
|
31097328 |
2019 |
|
Hamartoma Syndrome, Multiple
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Levels of GDF-15 were determined in serial plasma samples (0-120 h) from 177 CS patients in the CardShock study.
|
31310811 |
2019 |
|
Hyperglycemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Circulating levels of GDF-15 are associated with hyperglycaemia among people with obesity or diabetes, but longitudinal evidence on the association between GDF-15 levels and diabetes risk is scarce.
|
30350239 |
2019 |
|
Leukodystrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Although GDF-15 showed better analytical characteristics (sensitivity = 0.66, specificity = 0.64, area under the curve [AUC] = 0.88) compared to FGF-21 (sensitivity = 0.51, specificity = 0.76, AUC = 0.78) in the pediatric group of mitochondrial diseases, both markers were also elevated in a variety of non-mitochondrial diseases, especially those with liver involvement (Gaucher disease, galactosemia, glycogenosis types 1a, 1b, 9), organic acidurias and some leukodystrophies.
|
31260105 |
2019 |